VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
QTRX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
QTRXQuanterix Corporation
$4.29$201M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

QTRX logoQuanterix Corporation(QTRX)Earnings, Financials & Key Ratios

QTRX•NASDAQ
$4.29
Price updated Jul 6, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryDevice suppliers, distribution, and services
AboutQuanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.Show more
  • Revenue$139M+2.4%
  • EBITDA-$91M-105.4%
  • Net Income-$107M-178.1%
  • EPS (Diluted)-2.51-151.0%
  • Gross Margin46.67%-22.1%
  • EBITDA Margin-65.55%-100.6%
  • Operating Margin-79.2%-103.9%
  • Net Margin-77.28%-171.6%
  • ROE-34.25%-202.2%

QTRX Price & Volume

Quanterix Corporation (QTRX) stock price & volume — 10-year historical chart

Loading chart...

Persistent Cash Burn Threatens Proteomics Growth Trajectory

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall

Key Thesis Takeaways

  • Quanterix faces a precarious transition from research-based services to clinical diagnostics, characterized by extreme revenue volatility and a failure to achieve operating scale.
  • While the company attempts to pivot its business model, the rapid erosion of its cash position from $174.4M in 2023Q4 to $36.2M in 2026Q1 suggests an urgent need for capital that may dilute existing shareholders.
  • Investors should remain cautious as the company struggles to manage its cost structure, evidenced by a -113.6% operating margin in 2026Q1.

Verdict Logic

the company's liquidity buffer has been severely depleted, with cash and equivalents falling to $36.2M in 2026Q1 against a backdrop of consistent quarterly operating losses.

QTRX Growth Metrics

Quanterix Corporation (QTRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years27.53%
5 Years9.93%
3 Years9.53%
TTM8.18%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-117.64%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-90.32%

Return on Capital

10 Years-42.82%
5 Years-19.32%
3 Years-18.86%
Last Year-31%

QTRX Recent Earnings

Quanterix Corporation (QTRX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.39-25.8%
$0.31
Rev
$36M-1.2%
$37M
Q2 2026
Mar 2, 2026
Metric
Actual
Est
EPS
$0.38-40.7%
$0.27
Rev
$44M+14.8%
$38M
Q4 2025
Nov 10, 2025
Metric
Actual
Est
EPS
$0.36-56.5%
$0.23
Rev
$40M+5.8%
$38M
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.47-14.6%
$0.41
Rev
$24M-36.5%
$39M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.39vs $0.31-25.8%
$36Mvs $37M-1.2%
Q2 2026Mar 2, 2026
$0.38vs $0.27-40.7%
$44Mvs $38M+14.8%
Q4 2025Nov 10, 2025
$0.36vs $0.23-56.5%
$40Mvs $38M+5.8%
Q3 2025Aug 7, 2025
$0.47vs $0.41-14.6%
$24Mvs $39M-36.5%
Based on last 12 quarters of dataView full earnings history →

Latest QTRX News

Recent stock market news and headlines for Quanterix Corporation (QTRX)

Business Wire·Jun 16, 2026
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement Grants”) were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of 336,804 restricted stock units (“RSUs”) representing 336,804 shares of Quanterix commo.

Peers Comparison

Key metrics vs top competitors for Quanterix Corporation (QTRX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
QTRX logoQTRXQuanterix CorporationCurrent
$4.29$201.37M-1.712.38%-77.28%-34.25%—
SEER logoSEERSeer, Inc.
$2.19$120.41M-1.7115.57%-468.74%-26.58%—
CDNA logoCDNACareDx, Inc
$29.06$1.5B-72.6513.79%-1.98%-2.61%—
NTRA logoNTRANatera, Inc.
$283.80$40.64B-186.7135.9%-9.05%-15.13%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$313.50$9.06B-23.26-100%—-43.02%—
BIO logoBIOBio-Rad Laboratories, Inc.
$295.15$7.97B10.590.65%6.52%2.4%—

Compare QTRX vs Peers

Quanterix Corporation (QTRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SEER

Most directly comparable listed peer for QTRX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare QTRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs SEER, CDNA, NTRA, PRAX

QTRX SEC Filings & Documents

Quanterix Corporation (QTRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 2, 2026·SEC

Material company update

Jan 8, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 17, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 6, 2026·SEC

FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when QTRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

QTRX Frequently Asked Questions

Quanterix Corporation (QTRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Quanterix Corporation's revenue?

Quanterix Corporation (QTRX) reported $144.9M in revenue for fiscal year 2025. This represents a 1089% increase from $12.2M in 2015.

How fast is Quanterix Corporation growing?

Quanterix Corporation (QTRX) grew revenue by 2.4% over the past year. Growth has been modest.

Is QTRX profitable?

Quanterix Corporation (QTRX) reported a net loss of $104.2M for fiscal year 2025.

Dividend & Returns
What is QTRX's return on equity?

Quanterix Corporation (QTRX) has a return on equity (ROE) of -34.2%. Negative ROE indicates the company is unprofitable.

What is Quanterix Corporation's free cash flow?

Quanterix Corporation (QTRX) had negative free cash flow of $82.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in QTRX back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →